[
  {
    "ts": null,
    "headline": "Baron Health Care Fund Q4 2024 Shareholder Letter",
    "summary": "Baron Health Care Fund retreated in the fourth quarter of 2024, in line with its benchmark, the Russell 3000 Health Care Index. Read more here.",
    "url": "https://finnhub.io/api/news?id=0271890740cb4d946feb67364f9ef0cbee944c4e8517254a2ede741d5201d864",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737543300,
      "headline": "Baron Health Care Fund Q4 2024 Shareholder Letter",
      "id": 132442862,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154850841/image_2154850841.jpg?io=getty-c-w1536",
      "related": "TMO",
      "source": "SeekingAlpha",
      "summary": "Baron Health Care Fund retreated in the fourth quarter of 2024, in line with its benchmark, the Russell 3000 Health Care Index. Read more here.",
      "url": "https://finnhub.io/api/news?id=0271890740cb4d946feb67364f9ef0cbee944c4e8517254a2ede741d5201d864"
    }
  },
  {
    "ts": null,
    "headline": "Polen Focus Growth Portfolio Q4 2024 Commentary",
    "summary": "In the fourth quarter of 2024, the Polen Focus Growth Portfolio returned 4.88% gross of fees, and 4.65% net of fees. Read more here.",
    "url": "https://finnhub.io/api/news?id=debd6f11ca5423d15cd2f2e8eecd260bc3affa09f60c049f49877a62cbc0f302",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737523200,
      "headline": "Polen Focus Growth Portfolio Q4 2024 Commentary",
      "id": 132441306,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/165180102/image_165180102.jpg?io=getty-c-w1536",
      "related": "TMO",
      "source": "SeekingAlpha",
      "summary": "In the fourth quarter of 2024, the Polen Focus Growth Portfolio returned 4.88% gross of fees, and 4.65% net of fees. Read more here.",
      "url": "https://finnhub.io/api/news?id=debd6f11ca5423d15cd2f2e8eecd260bc3affa09f60c049f49877a62cbc0f302"
    }
  },
  {
    "ts": null,
    "headline": "Biologicals Is The Future In Thermo Fisher: Buy Rating",
    "summary": "Thermo Fisher Scientific (TMO) offers growth potential with diverse revenue streams, fair valuation, and strong CAGR projections for investors in 2025. See more.",
    "url": "https://finnhub.io/api/news?id=ee6e997f1887a046940edae0c2645abd8fa07ba18095dd51ab409daf31188880",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737510535,
      "headline": "Biologicals Is The Future In Thermo Fisher: Buy Rating",
      "id": 132440364,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1206874262/image_1206874262.jpg?io=getty-c-w1536",
      "related": "TMO",
      "source": "SeekingAlpha",
      "summary": "Thermo Fisher Scientific (TMO) offers growth potential with diverse revenue streams, fair valuation, and strong CAGR projections for investors in 2025. See more.",
      "url": "https://finnhub.io/api/news?id=ee6e997f1887a046940edae0c2645abd8fa07ba18095dd51ab409daf31188880"
    }
  }
]